Combinations of epinastine, methylephedrine and pseudoephedrine as new Pharmaceutical formulations

摘要

Refers to an oral Pharmaceutical composition containing: a) 2 - 25 mg of epinastine; b) 10 to 240 mg of methylephedrine; (c) 10 - 300 mg pseudoephedrine; (d) a pharmaceutically acceptable vehicle or component under the condition that the composition does not contain Belladonna.This composition is a compressed Double Layer where the layer contains methylephedrine and pseudoephedrine sustained Release and Instant Release Layer B containing epinastine being useful in the treatment of symptoms associated with colds, Cough, and / or other allergic ENERMEDADES ENFE Rmedades likely allergic origin